Usage of Inhaled Nitric Oxides in Cases of Eisenmenger

Eisenmenger Syndrome is congenital heart disease with pulmonary
hypertension and shunting from right to left turning. Pulmonary vascular
resistance defects cause enlargement of the pulmonary arteries, as well as
enlargement of the left ventricle. Hypoxia alveoli cause reversible
vasoconstriction which increases the pressure of the pulmonary wedges.
Physiological effects of inhaled nitric oxide therapy result in selective
pulmonary vasodilation such that the pulmonary wedge pressure can be
reduced. Although it does not affect the cardiac output and systemic arterial
pressure. Inhaled nitric oxide in the pulmonary vascular is selective as it is
activated by hemoglobin; selective vasodilatation in the ventilated region,
local hypoxia alveoli constricts the surrounding vascular tissue and
redistributes better and higher intraalveolar oxygen pressure to the
ventilated lungs. Inhaled nitric oxide improves this process by increasing
blood flow into a well-ventilated lung; bronchodilators; pulmonary
surfactant; combining high concentrations of inspired oxygen with high
concentrations of inhaled nitric oxide reduces minimum surface tension.
Keywords: inhalation nitric oxides, Eisenmenger syndrome, pulmonary
vascular